


Claims:

1. A compound of formula (I):



(I)

wherein:

A is a direct bond or C₁₋₂alkylene; wherein said C₁₋₂alkylene may be optionally substituted by one or more R²²;

Ring C is carbocyclyl or heterocyclyl;

- 10 R¹ and R⁴ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R¹ and R⁴ independently of each other may be optionally substituted on carbon by one or more R⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R⁹;

- 20 R² is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein
25 R² may be optionally substituted on carbon by one or more R¹⁰; and wherein if said

heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹¹;

R³ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R³ may be optionally substituted on carbon by one or more R¹²; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹³;

R⁵ is hydrogen or optionally substituted C₁₋₆alkyl; wherein said optional substituents are selected from one or more R¹⁴;

R⁶ and R⁷ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁶;

or R⁶ and R⁷ together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R¹⁷; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁸;

n = 0, 1, 2 or 3; wherein the values of R³ may be the same or different;

R⁸, R¹⁰, R¹², R¹⁴, R¹⁵, R¹⁷ and R²² are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino,

N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R⁸, R¹⁰, R¹², R¹⁴, R¹⁵, R¹⁷ and R²² independently of each other may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

R⁹, R¹¹, R¹³, R¹⁶, R¹⁸ and R²⁰ are independently selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R⁹, R¹¹, R¹³, R¹⁶, R¹⁸ and R²⁰ independently of each other may be optionally substituted on carbon by one or more R²¹;

R¹⁹ and R²¹ are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R¹⁹ and R²¹ independently of each other may be optionally substituted on carbon by one or more R²³; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴;

R²³ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylaminomethyl, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl; and

R²⁴ is selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not:

5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-bromo-N²-[1-(3-methyl-5-isoxazolyl)ethyl]-N⁴-(5-methyl-1H-pyrazol-3-yl)-2,4-

5 pyrimidinediamine;

5-chloro-N²-[1-(3-methyl-5-isoxazolyl)ethyl]-N⁴-(5-methyl-1H-pyrazol-3-yl)-2,4-

pyrimidinediamine;

5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;

10 5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine;

5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine; or

5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)ethyl]-2,4-pyrimidinediamine.

2. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according

15 to claim 1 wherein A is a direct bond.

3. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according
either claim 1 or 2 wherein Ring C is phenyl, thienyl, pyridyl, thiazolyl.

20 4. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according
to any one of claims 1-3 wherein R¹ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy,
N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkylS(O)_a wherein a is 0 or carbocyclyl; wherein R¹ may be
optionally substituted on carbon by one or more R⁸; wherein R⁸ is selected from halo or
carbocyclyl.

25

5. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according
to any one of claims 1-4 wherein R⁴ is hydrogen.

6. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according
30 to any one of claims 1-5 wherein:

R² is selected from C₁₋₆alkyl; wherein R² may be optionally substituted on carbon by
one or more R¹⁰;

R^{10} is selected from halo, hydroxy, carboxy, amino, C_{1-6} alkoxy, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl or heterocyclyl; wherein R^{10} may be optionally substituted on carbon by one or more R^{19} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{20} ;

R^{19} is selected from hydroxy or C_{1-6} alkoxy;

R^{20} is selected from C_{1-6} alkyl.

7. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to ant one of claims 1-6 wherein R^3 is selected from halo, nitro, C_{1-6} alkyl or C_{1-6} alkoxy; wherein R^3 may be optionally substituted on carbon by one or more R^{12} ; and R^{12} is selected from halo.

8. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1-7 wherein R^5 is hydrogen or optionally substituted C_{1-6} alkyl; wherein said optional substituents are selected from one or more R^{14} ; and R^{14} is selected from hydroxy.

9. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1-8 wherein:

R^6 and R^7 are independently selected from hydrogen, halo, nitro, cyano, amino, C_{1-6} alkyl, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, N -(C_{1-6} alkyl)carbamoyl, C_{1-6} alkoxycarbonyl or heterocyclyl; wherein R^6 and R^7 independently of each other may be optionally substituted on carbon by one or more R^{15} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{16} ;

or R^6 and R^7 together with the pyrimidine bond to which they are attached form a 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R^{17} ; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{18} ;

R¹⁵ is selected from halo, hydroxy, amino, C₁₋₆alkoxy, *N,N*-(C₁₋₆alkyl)₂amino, carbocyclyl or heterocyclyl; wherein R¹⁵ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

5 R¹⁷ is selected from halo, C₁₋₆alkyl or C₁₋₆alkoxy; wherein R¹⁷ may be optionally substituted on carbon by one or more R¹⁹;

R¹⁶ is selected from C₁₋₆alkyl;

R¹⁸ is selected from C₁₋₆alkanoyl;

10 R¹⁹ is selected from halo, hydroxy, C₁₋₆alkoxy or heterocyclyl; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴;

R²⁰ is selected from C₁₋₆alkyl; and

R²⁴ is selected from C₁₋₆alkyl.

15 10. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1-9 wherein n = 0 or 1.

11. A compound of formula (I) (as depicted in claim 1) wherein:

A is a direct bond;

20 Ring C is phenyl, thienyl, pyridyl, thiazolyl;

R¹ is selected from hydrogen, methyl, ethyl, isopropyl, *t*-butyl, trifluoromethyl, cyclopropylmethyl, benzyl, methoxy, ethoxy, propoxy, isopropoxy, sec-butoxy, dimethylamino, methylthio or cyclopropyl;

25 R² is selected from methyl, ethyl, trifluoromethyl, hydroxymethyl, carboxymethyl, aminomethyl, methoxymethyl, morpholinomethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-carboxyethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl, acetamidomethyl, 2-[*N*-methyl-*N*-(2-methoxyethyl)amino]ethyl, 2-[*N*-methyl-*N*-(2-hydroxyethyl)amino]ethyl, 2-(*N*-methylcarbamoyl)ethyl, 2-[*N*-(2-hydroxyethyl)carbamoyl]ethyl, 2-(*N,N*-dimethylcarbamoyl)ethyl, 2-morpholinoethyl, 2-pyrrolidin-1-ylethyl or 2-(1-methylpiperazin-
30 4-yl)ethyl, 1-methyl-2-hydroxyethyl;

R³ is selected from fluoro, nitro, trifluoromethyl or methoxy;

R⁴ is hydrogen;

R⁵ is hydrogen, methyl or 2-hydroxyethyl;

R⁶ and R⁷ are independently selected from hydrogen, fluoro, chloro, bromo, nitro, cyano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, *N*-methyl-*N*-propylamino, *N*-ethylcarbamoyl, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morpholino, pyrrolidinyl or piperazinyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R¹⁶;

or R⁶ and R⁷ together with the pyrimidine to which they are attached form a bicyclic ring selected from quinazolinyl, thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, 1*H*-pyrazolo[3,4-*d*]pyrimidinyl, thieno[3,4-*d*]pyrimidinyl, pyrido[2,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[4,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-*d*]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-*d*]pyrimidinyl; and wherein said bicyclic ring may be optionally substituted on carbon by one or more R¹⁷; and wherein said 5,6,7,8-tetrahydro-pyrido[4,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-*d*]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-*d*]pyrimidinyl may be optionally substituted on nitrogen by a group selected from R¹⁸;

R¹⁵ is selected from fluoro, hydroxy, amino, ethoxy, dimethylamino, phenyl, pyrrolidinyl, piperazinyl or morpholino; wherein R¹⁵ may be optionally substituted on carbon by one or more R¹⁹; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R²⁰;

R¹⁶ is selected from methyl;

R¹⁷ is selected from fluoro, chloro, methyl, methoxy, ethoxy or propoxy; wherein R¹⁷ may be optionally substituted on carbon by one or more R¹⁹;

R¹⁸ is selected from acetyl;

R¹⁹ is selected from fluoro, hydroxy, methoxy, piperazinyl, pyrrolidinyl or morpholino; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R²⁴;

R²⁰ is selected from methyl;

R²⁴ is selected from methyl;

n = 0 or 1;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not:

5-bromo-N⁴-(5-methyl-1*H*-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-chloro-N⁴-(5-methyl-1*H*-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine;
 5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine; or
 5 5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)ethyl]-2,4-pyrimidinediamine.

12. A compound of formula (I) (as depicted in claim 1) selected from:

(2R)-2-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoropyrimidin-2-yl} amino)-2-(4-fluorophenyl)ethanol;

10 5-bromo-N⁴-(3-cyclopropyl-1H-pyrazol-5-yl)-N²-[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine;

(2R)-2-({5-chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl} amino)-2-(4-fluorophenyl)ethanol;

15 (2R)-2-({5-chloro-4-[(3-isopropoxy-1H-pyrazol-5-yl)amino]pyrimidin-2-yl} amino)-2-(4-fluorophenyl)ethanol;

(3S)-3-({5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl} amino)-3-(4-fluorophenyl)-N-methylpropanamide;

2-({5-chloro-2-([(1S)-1-(4-fluorophenyl)ethyl]amino)-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]pyrimidin-4-yl} amino)propane-1,3-diol;

20 2-[(5-chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-([(1S)-1-(4-fluorophenyl)ethyl]amino)pyrimidin-4-yl)amino]propane-1,3-diol;

5-chloro-N⁴-(5-cyclopropyl-1H-pyrazol-3-yl)-N²-[(1S)-(4-fluoro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-pyrimidine-2,4-diamine;

25 (2R)-2-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-7-fluoroquinazolin-2-yl} amino)-2-(4-fluorophenyl)ethanol; and


2-[(5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-([(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino)pyrimidin-4-yl)amino]propane-1,3-diol;

or a pharmaceutically acceptable salt thereof.

30 13. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, which process comprises of:


Process a) reaction of a pyrimidine of formula (II):

- 138 -



(II)

wherein L is a displaceable group; with an pyrazole amine of formula (III):




(III)

5


or

Process b) reacting a pyrimidine of formula (IV):



(IV)


10 wherein L is a displaceable group; with a compound of formula (V):




(V)

Process c) reacting a compound of formula (VI):

- 139 -




with a compound of formula (VII):



5

wherein X is an oxygen atom and q is 1; or X is a nitrogen atom and q is 2; and wherein each R²⁰ independently represents a C₁₋₆alkyl group; or

Process d) reacting a compound of formula (VIII):



10

with hydrazine; or

and thereafter if necessary:

i) converting a compound of the formula (I) into another compound of the formula (I);

ii) removing any protecting groups;

15 iii) forming a pharmaceutically acceptable salt.

14. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, for use as a medicament.

15. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof,
5 as claimed in any one of claims 1-12, in the manufacture of a medicament for use in the inhibition of Trk activity.

16. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof,
10 as claimed in any one of claims 1-12, in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.

17. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof,
as claimed in any one of claims 1-12, in the manufacture of a medicament for use in the
production of an anti-proliferative effect.

18. A method of inhibiting Trk activity comprising administering to a host in need of such
15 treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12.

19. A method for the treatment or prophylaxis of cancer comprising administering a
20 therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12.

20. A method of producing an anti-proliferative effect in a warm-blooded animal, such as
25 man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12.

21. A pharmaceutical composition comprising a compound of formula (I), or a
30 pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, together with at least one pharmaceutically acceptable carrier, diluent or excipient.

22. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the inhibition of Trk activity.

5

23. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancer.

10

24. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.

15

25. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, for use in the inhibition of Trk activity.

20

26. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, for use in the treatment or prophylaxis of cancer.

27. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, for use in the production of an anti-proliferative effect.

25

28. The method or use according to claims 16, 19, 23 or 26 wherein said cancer is selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposi sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, leukaemia, tumours of the central and peripheral nervous system, melanoma, fibrosarcoma and osteosarcoma.

30